Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash

Novo Nordisk sharply reduced cash prices for its GLP‑1 drugs—offering the first two monthly doses of Wegovy and Ozempic for $199 (promo through end‑March) and cutting other self‑pay pricing to $349/month from $499 (2 mg Ozempic unchanged at $499)—via its direct‑to‑consumer channel and partners including Costco, GoodRx and Weight Watchers. The move is designed to counter rising competition from Eli Lilly and lower‑cost compounding pharmacies and follows a Trump administration agreement that will broaden Medicare/Medicaid access and set initial direct‑to‑consumer GLP‑1 prices around $350/month (targeting ~$250 over two years) with an anticipated TrumpRx launch in early 2026. With list prices for GLP‑1s near $1,000–$1,350 and cash sales representing roughly 10% of Wegovy scripts, the pricing shift aims to regain share but will likely compress ASPs and margins while potentially accelerating self‑pay uptake.

Analysis

Novo Nordisk on Monday cut cash prices for its GLP-1 drugs: the first two monthly doses of Wegovy and Ozempic are being offered at $199 through the end of March, other self-pay pricing is reduced to $349/month from $499 (the 2 mg Ozempic remains $499), and discounts are available via the company’s direct-to-consumer channel and partners including Costco, GoodRx and Weight Watchers and more than 70,000 pharmacies. Management said the cash market is roughly 10% of Wegovy prescriptions in the U.S., and the move follows prior half-price actions and competitive pressure from Eli Lilly and compounding pharmacies.

The announcement is explicitly defensive: BMO’s Evan Seigerman frames the cuts as a reaction to softening market share, and Eli Lilly’s starter Zepbound pricing ($349 starter; $499 higher doses) and compounding alternatives are cited as direct comparators. Concurrently, a Trump administration agreement targets average direct-to-consumer injectable GLP-1 pricing near $350/month initially and about $250 over two years with a planned TrumpRx launch in early 2026, while list prices remain roughly $1,000–$1,350.

Implications are twofold: the price actions should support near-term volume and self-pay uptake but will compress average selling prices and likely margins, increasing uncertainty around U.S. ASPs and reimbursement for weight-loss indications where coverage is spotty; monitor shifts in cash-channel share, margin impact and the evolving competitive response from Eli Lilly and compounding pharmacies.

Key Decisions for Investors

• It may be prudent to trim or hedge NVO exposure near term given likely ASP compression and margin pressure from aggressive self-pay discounts and compounding competition,
• Consider maintaining or modestly increasing exposure to Eli Lilly as a potential relative beneficiary if it sustains pricing and share gains amid the market reshuffle,
• Monitor three leading indicators before changing material positions: weekly/monthly self-pay volume and cash-channel share (current cash = ~10% of Wegovy scripts), competitive pricing from compounding pharmacies and rivals, and any TrumpRx timeline or announced ASP reductions toward ~$250 over two years